Boardroom Alpha
Boardroom Alpha
PCVX · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Vaxcyte Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
PCVX
Accession
0001193125-26-173686
Boardroom Alpha · Filing insights

VAXCYTE, INC. board recommends voting For all three proposals at the 2026 annual meeting.

About Vaxcyte Inc
Market cap
$6.8B
1Y TSR
+51.6%
3Y TSR
+0.2%
Board grade
C+
Sector
Healthcare
CEO
Grant Pickering
Last annual meeting: Jun 15, 2026 · View full Vaxcyte Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Under § 240.14a-12

VAXCYTE, INC.

(Name of Registrant as Specified in its Charter)

N/A

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit requirement by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 
 


LOGO

You invested in VAXCYTE, INC. and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 15, 2026.

Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 1, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

 

LOGO

* Please check the meeting materials for any special requirements for meeting attendance.


Vote at www.ProxyVote.com

 

 

 

THIS IS NOT A VOTABLE BALLOT

 

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. Before voting, we encourage you to access and review the proxy materials, which contain important information and are available on the Internet or by mail.

 

 

 Voting Items  

Board 

Recommends 

 
 1.  

Election of Class III Directors

 

LOGO  For

 

Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal.

 

 

Nominees:

 

 

01) Olivier Brandicourt, M.D.

  02) Halley Gilbert, J.D.
 
    03) Grant E. Pickering, M.B.A.    
 
 2.   Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.   LOGO  For
 
 3.   Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers.   LOGO  For

NOTE: The proxies may vote in their discretion upon any other business that may properly come before the meeting or any adjournment thereof.

 
 

 

 

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

 

 

          
          
V94653-P48490   

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Vaxcyte Inc (PCVX)

Reference

Frequently asked questions

When did Vaxcyte Inc file this DEFA14A?
Vaxcyte Inc (PCVX) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001193125-26-173686.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
VAXCYTE, INC. board recommends voting For all three proposals at the 2026 annual meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Vaxcyte Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Vaxcyte Inc has filed under CIK 1649094, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer